Investment Rating - The report maintains an "Overweight" rating for the pet economy sector, highlighting its rapid growth during the Spring Festival [4][7]. Core Insights - The pet consumption during the Spring Festival has seen significant growth, with a 20%+ year-on-year increase in searches for "New Year pet gift boxes" on Tmall. The sales of pet clothing surged by 330%, and pet New Year's dinners increased by 290% [7]. - The report emphasizes the comprehensive nature of pet services, with a 46% month-on-month increase in pet boarding demand. The expansion of pet transport services on high-speed trains and airlines is also noted [7]. - Upcoming pet exhibitions in March are expected to further stimulate market interest, with major brands likely to launch new products [7]. Summary by Sections Important Industry Data Overview - The agricultural sector index stands at 2,858.1, with a year-on-year increase of 14.28%. The wholesale price index for agricultural products is at 129.6, reflecting a 4.95% year-on-year increase [10]. - The average price of live pigs is 12.3 yuan/kg, down 15.81% year-on-year, while the average price of piglets is 471.0 yuan/head, down 25.24% year-on-year [10]. Pig Farming Sector - The report anticipates a seasonal decline in pig prices post-Spring Festival, with expectations of low prices leading to potential losses in farming [5][12]. - Recommended stocks in the pig farming sector include Muyuan Foods and Wens Foodstuffs, with additional recommendations in the agricultural product supply chain [5]. Poultry Sector - The report discusses the white feather broiler market, noting a decrease in chick prices and stable prices for broiler meat [19][20]. - The average price of broiler chicks is reported at 2.4 yuan/chick, with a 4.35% increase month-on-month [10]. Feed Sector - The report indicates stable feed prices, with corn prices at 2,372.2 yuan/ton and soybean meal prices at 3,167.7 yuan/ton [10][30]. - The analysis highlights the fluctuations in import prices for soybeans and corn, impacting the feed sector [32]. Key Company Profit Forecasts and Valuations - The report provides earnings per share (EPS) forecasts for key companies, with Muyuan Foods projected at 2.54 yuan for 2025 and 4.81 yuan for 2026, maintaining an "Overweight" rating [36]. - Other companies such as Wens Foodstuffs and Petty Holdings also receive "Overweight" ratings, indicating strong growth potential [36].

Investment Rating - The report maintains a "Recommendation" rating for the veterinary medicine industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [80]. Core Insights - In January, the majority of vaccine varieties saw a year-on-year decline in batch approvals, with the Veterinary Product Index (VPI) dropping 1.8% month-on-month, marking three consecutive months of decline [2][3]. - The report highlights that the overall performance of the animal vaccine and veterinary medicine sector has been affected by high base effects from the previous year, low breeding sentiment, and the timing of the Spring Festival impacting stocking rhythms [10][57]. - The report emphasizes the importance of innovation in driving performance, noting that companies demonstrating product, marketing, or capital operation innovations have shown better financial results [71][72]. Summary by Sections Vaccine Batch Approvals - In January, most vaccine products experienced a year-on-year decline in batch approvals. For pig vaccines, the majority saw declines, with only pseudorabies and blue ear vaccines showing increases of 13.1% and 30.2%, respectively. Other vaccines like foot-and-mouth disease and porcine circovirus vaccines saw declines ranging from 20% to 50% [9][10]. - In the poultry vaccine segment, the H5N1 trivalent vaccine and Marek's vaccine saw declines of 13.8% and 25.9%, respectively, while the newcastle disease vaccine remained flat [9][10]. Veterinary Raw Materials - The VPI index averaged 66.16 in January, down 1.8% from December, with a continued downward trend observed in the prices of most raw materials. For instance, the price of florfenicol dropped by 4.5% month-on-month, while amoxicillin saw a slight increase of 0.7% [57][58]. - Year-on-year comparisons show that while some products like tylosin and tilmicosin have seen significant price increases, amoxicillin has dropped by 28.8% [58][57]. Investment Recommendations - The report suggests focusing on undervalued companies with improvement logic, highlighting that the ongoing industry competition has led to a market environment where only innovative companies are likely to thrive. Recommended companies include Zhongmu Co., Ltd., Reap Bio, and others [71][73].

Group 1: Market Trends Post-Spring Festival - The Shanghai Composite Index shows a significant upward trend after the Spring Festival, with probabilities of increases over 5, 10, 20, and 30 days being 75%, 70%, 80%, and 60% respectively, and median gains of 1.64%, 1.32%, 9.45%, and 3.88% [1] - Over the past decade, the coal, agriculture, forestry, animal husbandry, and defense industries have performed well in the month following the Spring Festival, with the computer industry leading in the last two years [1] Group 2: Industry Performance Data - Historical data shows varying performance across industries during the Spring Festival period, with coal, environmental protection, and agriculture showing notable gains in specific years, such as coal in 2016 with a maximum gain of 10.34% and agriculture in 2019 with a maximum gain of 19.78% [2] - The report indicates that the coal industry is expected to see a significant increase in production capacity in 2026, with an anticipated rise of 0.7 billion tons, while also highlighting a potential reduction in capacity by 1.5 billion tons due to policy changes [2] Group 3: Agricultural Sector Insights - The agricultural sector is projected to experience a gradual recovery in pig prices by 2026, driven by a reduction in breeding sow capacity, which is expected to improve profitability for leading pig farming companies [3] - The report emphasizes opportunities in the poultry sector, particularly for leading chicken farming companies, and highlights the growth potential in the pet market [3] Group 4: Defense Industry Outlook - The defense industry is poised for growth in 2026, driven by geopolitical factors and advancements in military technology, with a focus on precision-guided munitions, unmanned systems, and networked battlefield capabilities [4] - Key recommendations include investments in missile weaponry, new aviation equipment, unmanned systems, and commercial aerospace sectors, with specific companies highlighted for their strategic positions within these industries [5]

Market Trends - The Shanghai Composite Index shows a significant "spring market" trend with a 75% probability of rising in the first five days after the Spring Festival, and a median increase of 1.64% [1] - Over the past decade, the coal, agriculture, forestry, animal husbandry, and military industries have performed well in the month following the Spring Festival, with the computer industry leading in the last two years [1] Industry Performance - In the past ten years, various industries have shown different performances post-Spring Festival, with coal, environmental protection, national defense, agriculture, and steel industries having notable fluctuations in their weekly and monthly gains [2] - The coal industry is expected to see a significant increase in production capacity in 2026, with an anticipated rise of 70 million tons in raw coal output, while policies may lead to a reduction of 150 million tons in capacity [2] Agricultural Sector Insights - The pig breeding sector is expected to see a gradual recovery in prices and profitability by 2026 due to ongoing capacity reduction in breeding sows [3] - The poultry farming sector is also expected to improve, with opportunities for leading companies in the meat chicken breeding market [3] Defense and Aerospace Industry - The defense industry is poised for growth in 2026, driven by geopolitical tensions and advancements in military technology, with a focus on precision-guided munitions and unmanned systems [4] - The commercial aerospace sector is expected to experience a boom, with several new rocket launches planned and advancements in reusable technology [4] Recommended Companies - In the defense sector, companies such as North Navigation, AVIC Shenyang Aircraft Corporation, and Inner Mongolia First Machinery Group are highlighted for their strategic positions in precision-guided munitions, new aircraft development, and unmanned systems [5] - In the commercial aerospace sector, Aerospace Electric and Guobo Electronics are recommended for their roles in providing critical components for satellite and rocket technologies [5]

Group 1 - The article highlights the establishment of various mother funds across different regions in China, focusing on sectors such as artificial intelligence, medical devices, and high-end manufacturing [2][4][6] - A significant fund cluster exceeding 70 billion yuan was launched in Nanjing, emphasizing early-stage investments in hard technology [4][6] - The Hunan province has set a target scale of 100 billion yuan for its aerospace and marine fund, while Hubei has introduced a 30 billion yuan fund focusing on artificial intelligence [2][29][30] Group 2 - The Shanghai Future Industry Fund announced plans to establish nine sub-funds, indicating a strong commitment to supporting innovative sectors [3] - The Jiangsu province has launched a 100 billion yuan market-oriented mother fund aimed at fostering long-term competitive enterprises [4][6] - The establishment of a 50 billion yuan second phase of the Baoyuehu Science and Technology Mother Fund in Nantong, focusing on AI and deep integration industries, was also noted [9] Group 3 - The Sichuan and Chongqing regions are actively selecting general partners for mother funds, indicating a concentrated effort to enhance investment in emerging technologies [2][6] - The establishment of a 20 billion yuan low-altitude economy fund in Chongqing aims to support the aerospace and low-altitude economy sectors [28] - The article mentions the successful registration of a 3 billion yuan health industry investment fund in Huangshi, focusing on biomedicine and health sectors [31] Group 4 - The article discusses the establishment of various funds targeting specific industries, such as the 10 billion yuan agricultural high-quality development fund in Guangdong [36] - The Shanghai Integrated Circuit Industry Investment Fund increased its capital to 60.3 billion yuan, reflecting a significant growth of approximately 1038% [34] - The establishment of a 20 billion yuan fund in Jiangsu by China Life and other partners focuses on AI, integrated circuits, and biomedicine [42] Group 5 - The article notes the establishment of a 2 billion yuan fund in Hechi, focusing on key metals, biomedicine, semiconductor materials, and AI [25] - The announcement of a 10 billion yuan fund in Ningxia aims to enhance the resilience and safety of industrial supply chains [21][22] - The establishment of a 10 billion yuan urban renewal development fund in Sanhe focuses on projects related to urban infrastructure and development [23]

瑞普生物做LP 导读： 上市公司密集设立并购基金，又一家LP入场。 作者丨黄蓉 时隔一年，瑞普生物又出手了。 2月12日，瑞普生物发布公告，称公司与海通并购（上海）私募基金管理有限公司、 海通开元投 资有限公司、高邮市产业引导基金（有限合伙）及关联方天津瑞晟私募基金管理有限公司签署《江 苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协议》，拟共同出资设立江苏国泰海通 瑞普并购产业基金合伙企业（有限合伙）。 根据公告，该基金总规模为人民币10亿元。其中，瑞普生物作为有限合伙人以自有资金及自筹资 金出资人民币2.95亿元，占合伙企业认缴出资总额的 29.50%。 此外， 作为有限合伙人， 海通开元出资2.05亿元，占认缴出资总额20.5%。高邮市产业引导基 金认购4.9亿元，占比49%。海通并 购（上海）私募基金管理有限公司作为基金普通合伙人和执 行事务合伙人，与 天津瑞晟私募基金管理有限公司各认缴500万元，占比0.5% 本基金投资期为5 年，退出期为2年。退出期后仍有存续项目的， 经合伙人会议同意可延长， 每 次不超过一年，最多不超过一次。 从投资方向看，此次产业并购基金主要以支持实体产业发展为导向，重 ...

Investment Rating - The report maintains an "Overweight" rating for the agriculture, forestry, animal husbandry, and fishery industry [1][53]. Core Insights - The SW agriculture, forestry, animal husbandry, and fishery industry slightly underperformed the CSI 300 index, declining by 2.88% from January 30, 2026, to February 12, 2026, which is approximately 2.16 percentage points lower than the index [7][14]. - Among the sub-sectors, only the fishery sector recorded positive returns, increasing by 0.27%, while feed, breeding, planting, agricultural product processing, and animal health sectors all experienced negative returns, with declines of 1.36%, 2.02%, 4.45%, 4.8%, and 7.3% respectively [15][19]. - The overall price-to-book (PB) ratio for the industry is approximately 2.61 times, reflecting a slight decline in valuation, and is at about 58.7% of the historical average since 2006, indicating a relatively low historical valuation level [22][24]. Industry Important Data - **Pig Farming**: - The average price of the national external three-line pigs fell from 12.52 CNY/kg to 11.57 CNY/kg during the reporting period [25]. - The cost of corn and soybean meal slightly decreased, with corn priced at 2372.16 CNY/ton and soybean meal at 3164 CNY/ton as of February 12, 2026 [27]. - Profitability for self-bred pigs was reported at -98.32 CNY/head, while for purchased piglets, it was 53.1 CNY/head, both showing a decline compared to the previous week [31]. - **Poultry Farming**: - The average price of broiler chicks increased to 2.4 CNY/chick, while the price for layer chicks remained stable at 3.2 CNY/chick as of February 13, 2026 [33]. - The average price for white feather broilers decreased to 7.48 CNY/kg, with profitability reported at -0.2 CNY/chick, indicating a decline from the previous week [36]. Industry News - The report highlights that the breeding capacity of sows is expected to continue decreasing in 2025, leading to a gradual reduction in pig supply and a potential increase in pig prices in 2026, which may improve breeding profitability [53]. - The report emphasizes the importance of monitoring the capacity reduction and the expected profitability improvement, particularly for leading companies in pig farming and poultry sectors [53]. Company Highlights - Key companies to watch include: - Muyuan Foods (牧原股份, 002714): A leading pig farming company with cost and scale advantages. - Wens Foodstuff Group (温氏股份, 300498): A major player in both pig and poultry farming with strong cost control. - Haida Group (海大集团, 002311): A leading feed company expected to maintain steady market share growth. - Shengnong Development (圣农发展, 002299): A leader in the white feather broiler industry with a strong supply chain. - Reap Bio (瑞普生物, 300119): A leader in the animal health sector with a growing product matrix for pet health [54].

Core Insights - The poultry vaccine industry is crucial for preventing infectious diseases in poultry and is the foundation of modern poultry farming disease control [1] - China, as a major poultry producer and consumer, has a stable poultry production growth, which provides a solid demand base for the poultry vaccine market [1][8] - The market for poultry vaccines is expected to expand due to increased investment in disease prevention and a shift towards precision immunization models [1][9] Industry Overview - Poultry vaccines are biological agents developed specifically for birds such as chickens, ducks, and turkeys, aimed at inducing specific immune responses to prevent or control infectious diseases [2][3] - The poultry vaccine market can be categorized based on technology, pathogen type, usage characteristics, and vaccination methods [3][4] Market Dynamics - The Chinese poultry vaccine industry has a complete and interconnected supply chain, with high technical barriers in R&D and core raw material supply [5][6] - The demand is driven by government procurement of high-pathogenic avian influenza vaccines and market purchases from large farming groups and small farms [6][8] Policy Environment - The Chinese government has implemented strict management regulations to ensure the quality of veterinary biological products, including several guidelines and policies from 2022 to 2025 [6][7] - The mandatory immunization policy for major diseases has stabilized the vaccine coverage rate at over 98.7%, reinforcing the foundation for disease control in poultry [8] Market Growth Projections - The poultry meat production in China is projected to grow from 23.61 million tons in 2020 to 28.37 million tons by 2025, with a compound annual growth rate of 3.74% [9] - The poultry vaccine market is expected to recover and grow to 69.5 billion yuan in 2024, driven by increasing poultry output and vaccination demand [11][12] Vaccine Segmentation - The poultry vaccine market is primarily composed of inactivated vaccines, live vaccines, and other types, with inactivated vaccines holding over 65% market share [12] - The market for inactivated vaccines is projected to reach 4.65 billion yuan in 2024, while the segment for other vaccines, including genetically engineered and multivalent vaccines, is expected to grow significantly [12] Future Trends - The poultry vaccine industry is anticipated to achieve high-quality development driven by technological innovation, market consolidation, and demand upgrades [13] - Multi-valent vaccines will become the main focus of research and development, with new technologies like mRNA and viral vector vaccines accelerating commercialization [14] - The industry is expected to transition from a single vaccine supply model to a comprehensive service model that includes vaccines, diagnostics, and customized immunization plans [16]

Group 1 - Major shareholder Han Yuanfu of Dayuan Pump Industry plans to reduce his stake by up to 3%, totaling no more than 5.595 million shares [1] - Hainan Highway, a shareholder of Haikou Group, intends to increase its stake in the company by no less than 40 million yuan and no more than 50 million yuan [2] - China Communications Construction Company signed new contracts worth 1.883672 trillion yuan in 2025, a year-on-year increase of 0.13% [3] Group 2 - The controlling shareholder of Quzhou Development proposed to repurchase shares worth between 100 million and 200 million yuan [4] - Shareholder Huang Song of Huibo Pu plans to reduce his stake by up to 1%, totaling no more than 1.3372 million shares [5] - The board secretary of Fusenmei has had his detention lifted and is now under investigation, allowing him to resume his duties [6] Group 3 - YN Holdings clarified that its investment target does not belong to the sectors of computing chip manufacturing, computing leasing, or cloud services [7] - Shareholder Euro Star Diamond plans to reduce its stake in Laishen Tongling by up to 3%, totaling no more than 1.029 million shares [8] - Shareholder Zhu Guangkui of Demar Technology plans to reduce his stake by up to 3%, totaling no more than 791.24 million shares [10] Group 4 - Newnow's subsidiary received approval for clinical trials of drug SYS6023 for breast cancer treatment [11] - Ruipubio plans to invest 295 million yuan to establish a merger and acquisition industry fund focusing on animal health and biomedicine [12] - Shareholder Ningbo Hutong plans to reduce its stake in Huitong Energy by up to 1%, totaling no more than 206.28 million shares [13] Group 5 - Chengda Bio's high-dose influenza virus vaccine has received approval for clinical trials [14] - Kang En Bei's subsidiaries participated in the national centralized procurement process, with selected drugs expected to generate 385 million yuan in sales in 2024 [15] - Weitang Industrial signed a strategic cooperation framework agreement with Amphenol to enhance product development and market collaboration [16] Group 6 - Terui De is the first candidate for a 137 million yuan EPC general contracting project [17] - Chen Zhan Optoelectronics plans to invest 650 million yuan to establish an overseas smart manufacturing base [19] - Zhang Yi Technology's AI short drama business revenue is expected to account for no more than 1% of total revenue in 2025 [20] Group 7 - Jiangshan Co. plans to reduce its stake by up to 3%, totaling no more than 4.3308 million shares [21] - Xie Chuang Data plans to procure servers from multiple suppliers, with a total expected expenditure of no more than 11 billion yuan [22] - Huaming Equipment is planning to issue H-shares and list on the Hong Kong Stock Exchange [23] Group 8 - Wenzhou Hongfeng plans to raise no more than 450 million yuan through a private placement for expansion projects [24] - Yingkerui plans to raise no more than 379 million yuan for various projects including smart power supply systems [25] - Jingrui Electric Materials plans to invest 600 million yuan to build a key materials base for the integrated circuit manufacturing industry [26] Group 9 - Beijing Bank's chairman resigned due to age [27] - Youkeshu's actual controller plans to increase his stake by no less than 50 million yuan and no more than 100 million yuan [28] - Hanbo High-tech's subsidiary plans to acquire assets to enter the wet electronic chemicals industry [29] Group 10 - Jia Mei Packaging clarified that its capital operations related to Magic Atom will be independent of the listed company [30] - International Composite Materials confirmed that electronic-grade glass fiber is a key raw material for PCBs [31] - Zhongyin Fashion plans to procure hardware simulation accelerators for 9.385 million USD [32] Group 11 - Haohai Biotechnology's shareholder plans to reduce his stake by up to 0.4337% [33] - United Optoelectronics plans to sign a framework contract with Lingzhi Cloud Creation for robot assembly services [34] - Qianfang Technology's major shareholder plans to reduce its stake by up to 1.5%, totaling no more than 2.36507 million shares [35] Group 12 - Xiamen Airport plans to acquire 100% of Zhaoxiang Technology for 1.193 billion yuan [36] - Tuoshan Heavy Industry plans to acquire 51% of Xin Kaiyuan for 219 million yuan [38] - Shenkai Co. plans to repurchase shares worth between 40 million and 80 million yuan [39] Group 13 - Hushun Co. plans to invest 3.3 billion yuan in a high-end PCB production project [40] - Zhengzhou Bank appointed Wang Sentao as vice president, pending regulatory approval [41]

针对上述提问，瑞普生物回应称："投资者您好！生物制品13%税率一般计税政策不影响2025年经营成 果；2026年实施后短期实际税负将有所上升。公司产品线齐全，产业链完善，通过优化产品定价与结 构，优化供应商与采购管理，降低税率调整带来的影响。公司严格依规纳税，扎实做好经营管理，为公 司及股东创造价值。相关情况请以公司定期报告披露为准。感谢您的理解与支持！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向瑞普生物提问："生物制品2026年1月1日由3%税额改为13%，对公司盈利水平影 响有多大？" 来源：市场资讯 ...